Research output

Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia

Research output: Contribution to journalArticleAcademicpeer-review

Associated researcher

Associated organisations

    Research areas

  • Alzheimer's disease, cerebrospinal fluid, cost-utility, economic evaluation, mild cognitive impairment, prognosis, risk, ASSOCIATION WORKGROUPS, DIAGNOSTIC GUIDELINES, MODIFYING TREATMENT, NATIONAL INSTITUTE, RECOMMENDATIONS, CRITERIA, IMPACT
View graph of relations


Original languageEnglish
Pages (from-to)1477-1487
Number of pages11
JournalJournal of Alzheimer's Disease
Issue number4
Publication statusPublished - 7 Nov 2017